TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be well tolerated in a preclinical toxicology study, supporting the company’s decision to test it in humans. No side effects were observed when lab animals were given a dose of TOL2…
News
High levels of serum fibrinogen were found to be a sensitive and specific biomarker to identify people with myasthenia gravis (MG), according to a recent study. Fibrinogen is a plasma protein that participates in blood clotting and is usually not present in the serum. In MG patients, residual fibrinogen…
The European Commission has approved Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of certain adults with generalized myasthenia gravis (gMG), closely following its clearance of Zilbrysq (zilucoplan) as an add-on treatment last month. These medications are sold by the biopharma company UCB.
Treatment with the experimental cell therapy Descartes-08 led to reductions in disease severity that were sustained out to one year for five of seven generalized myasthenia gravis (gMG) patients taking part in a Phase 2a clinical trial. That’s according to new data, announced by the therapy’s developer Cartesian Therapeutics,…
Zilbrysq (zilucoplan), a new treatment for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR), is now commercially available in the U.S., with a list price likely to exceed $30,000 for a 30-day supply. Approved by the U.S. Food and…
In 2023, Myasthenia Gravis News brought up-to-date coverage of the latest scientific research and developments in the treatment of myasthenia gravis (MG). Here are the 10 most-read news stories of 2023, along with a brief description of what made them relevant for our readers. We look forward to…
Three microRNAs (miRNAs) — small strands of RNA that regulate protein production — in blood samples accurately identified people with early-onset ocular myasthenia gravis (OMG) and distinguished them from early-onset generalized myasthenia gravis (gMG) patients and healthy people in a recent study. “These results suggested that the three…
Among caregivers of people with myasthenia gravis (MG) living in Northwest China, care burden rises with disease severity and the degree of the patient’s depression, a study reported. According to its researchers, this is primarily driven by patients’ inability to participate more fully in household chores, and the increasing…
A treatment course of low-dose rituximab eased measures of clinical severity, improved quality of life, and allowed lower steroid doses to be used in myasthenia gravis (MG) patients who have antibodies against muscle-specific tyrosine kinase (MuSK). That’s according to a small study in China that looked at a…
Myasthenia gravis (MG) patients on long-term treatment with intravenous immunoglobulin (IVIg) or nonsteroidal immunosuppressants have significantly higher rates of disease crises and exacerbations, and subsequent greater healthcare costs, according to a retrospective analysis of insurance claims from a U.S. database. Overall, these findings highlight that treatments capable of…
Recent Posts
- Women with MG have higher risk of complications during pregnancy
- This year, I’m pushing boundaries in how I live with MG
- Early rituximab treatment may improve long-term outcomes in gMG
- Vyvgart plus low-dose steroids is safer treatment for severe gMG: Study
- Guest Voice: Don’t let fear hold you back from living fully with MG